FDA Grants Accelerated Approval to Zongertinib for Unresectable or Metastatic Non-Squamous NSCLC By Ogkologos - March 18, 2026 131 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the Beamion LUNG-1 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Generic Palbociclib Metastasis-Directed Therapy for Oligometastatic Solid Tumours in Histology-Specific Context ctDNA Testing After Neoadjuvant Chemotherapy and Radical Cystectomy Predicts Recurrence Risk in Patients with MIBC MOST POPULAR Sacituzumab Govitecan Demonstrates a Relatively High ORR with Rapid Responses in... September 16, 2024 Can Being Exposed to Wildfire Smoke Affect Your Cancer Risk? February 1, 2024 Adding Blinatumomab to Consolidation Chemotherapy Improves OS in Adult Patients in... August 12, 2024 Helping Cancer Survivors Cope with Cancer-Related Anxiety and Distress April 30, 2020 Load more HOT NEWS Artificial Intelligence Brings Pancreatic Cancer Screening One Step Closer to Reality... EMA Recommends Granting a Marketing Authorisation for the Hybrid Medicine Imatinib Should People with Cancer and Cancer Survivors Get the Flu Vaccine? FDA Approves Nivolumab and Ipilimumab for Unresectable Malignant Pleural Mesothelioma
